Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Scandic in connection with its repurchase of convertible bonds
Mandate

Vinge has advised Scandic in connection with its repurchase of convertible bonds

November 20, 2023 Banking and Finance Capital Markets and Public M&A

Vinge has advised Scandic Hotels Group AB (publ) (”Scandic”) in connection with its repurchase of convertible bonds.

In total, convertible bonds with an aggregate nominal amount of SEK 590.2 million were repurchased through an modified Dutch auction procedure.

Scandic is the largest hotel company in the Nordic countries with a network of about 280 hotels with 58,000 rooms in operation and under development, in more than 130 destinations. Scandic is listed on Nasdaq Stockholm.

Vinge’s team has consisted of Jesper Schönbeck, Amanda Knutsson, William Kåge, Lovisa Jonassen (Capital markets and public M&A), Louise Brorsson Salomon and Arvid Weimers (Banking and finance)

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026